PATENT CLAIM ANALYSIS

Application Number: 16196955
Application Type: Utility
Filing Date: 2018-11
Publication Date: 2019-08
Patent Classification: ["514", "300000"]

Abstract:
The present invention relates to the use of cyclin-dependent kinase 9 (CDK9) inhibitors to reduce, inhibit and/or prevent cartilage degradation. CDK9 inhibitors can be used to reduce, inhibit and/or prevent cartilage degradation and loss of cartilage viability during allograft storage. CDK9 inhibitors can be used as a post-injury intervention treatment to reduce, inhibit and/or prevent the acute cellular responses that lead to future cartilage degradation and osteoarthritis.

Claim (Index 39):
The method of  claim 29 , wherein the CDK9 inhibitor or salt thereof is administered within about 4 days of injury.

Metadata:
- Claim Count in Document: 74.0
- Percentile: 98.0
- Lexical Diversity: 1.70455
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15356231', '14351878', '15517476', '10740098', '14481841']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.835231385718132
- 35 USC 102 Novelty (BERT): 0.6566752958189092
- Combined Prediction Score: 0.8173757767282098
- Mean Citation Score: 539.058552
- Max Citation Score: 740.2954
- Similarity Product: 569.2519903506518

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test